| European Medicines Agency - Eligible Group Status - COMP [Committee for Orphan Medicinal Products] - SAWP [Scientific Advice Working Party]. | 呼吸系统
> 肺纤维化 | 监管合作伙伴关系
> 与监管机构合作 | Not specified | International | Rarely | 119039359117 |
| When new drugs are approved by the EU medicines agency, we work to represent patient interest with the health service and government agency responsible for approving the drug in Ireland and regulating pricing of new drugs. | 呼吸系统
> 间质性肺疾病（ILD） | 监管合作伙伴关系
> 与监管机构合作 | 5,000 | National | Sometimes | 119044171823 |
| Submission on Lutathera for reimbursement decision. | 癌症
> 癌症：神经内分泌（NET） | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Rarely | 119039308095 |
| We share the patient experience of living with a condition as part of the reimbursement process. | 神经肌肉
> 神经肌肉疾病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 1,000 | National | Sometimes | 119047368493 |
| We submitted our support to the NCPE [National Centre for Pharmacoeconomics] for their appraisal of Lutathera [used to treat adults with certain unresectable or metastatic gastroenteropancreatic neuroendocrine tumors]. | 癌症
> 癌症：神经内分泌（NET） | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100 | National | Rarely | 119051190597 |
| Drugs for ataxia are very rare, so we only make submissions as they become available. | 神经退行性
> 共济失调 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | 1,000 | National | Rarely | 119020208311 |
| European Medicines Agency - Eligible Group Status - COMP [Committee for Orphan Medicinal Products] - SAWP [Scientific Advice Working Party]. | 呼吸系统
> 肺纤维化 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | Not specified | International | Rarely | 119039359117 |
| Meetings with Government Representatives and Department of Health regarding the availability of certain DMTs [Disease-Modifying Therapies primarily used for multiple sclerosis and various autoimmune conditions (like rheumatoid arthritis)]. | 神经系统
> 多发性硬化症 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Regularly | 119074666617 |
| National organization is affiliated with European groups which attempt to have influence. | 总体健康
> 健康素养 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | National | Rarely | 119052876993 |
| Advocacy/public affairs messaging about improving reimbursement decision-making for drugs in Ireland. | 癌症
> 癌症：大多数类型 | 影响政策和立法
> 影响医疗保健政策和立法 | 10,000 | National | Rarely | 119063937918 |
| We have advocated for our members to our government representatives at yearly events where we have been invited to government buildings to present to an invited group. | 患者权益倡导
> 健康活动人士 | 影响政策和立法
> 参与公众听证会和咨询 | 5,000 | National | Rarely | 119047297038 |
| We have advocated for our members to our government representatives at yearly events where we have been invited to government buildings to present to an invited group. | 患者权益倡导
> 健康活动人士 | 影响政策和立法
> 动员议员和政治领导人 | 5,000 | National | Rarely | 119047297038 |
| We advocate for the most efficient medicine to be available and reimbursed for heart failure patients. | 心脏
> 心力衰竭 | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 5,000 | National | Sometimes | 119051411038 |
| When new drugs are approved by the EU medicines agency, we work to represent patient interest with the health service and government agency responsible for approving the drug in Ireland and regulating pricing of new drugs. | 呼吸系统
> 间质性肺疾病（ILD） | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 5,000 | National | Sometimes | 119044171823 |
| Advocacy/public affairs messaging about improving reimbursement decision-making for drugs in Ireland. | 癌症
> 癌症：大多数类型 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 10,000 | National | Rarely | 119063937918 |
| Equity of access: Public patients can wait a lot longer for access to meds approved by EMA [European Medicines Agency], versus private patients whose insurance companies reimburse. | 患者权益倡导
> 健康活动人士 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | National | Sometimes | 119044976833 |
| We advocate for the most efficient medicine to be available and reimbursed for heart failure patients. | 心脏
> 心力衰竭 | 改善访问路径
> 促进公平获取药品/医疗保健 | 5,000 | National | Sometimes | 119051411038 |
| Meetings with Government Representatives and Department of Health regarding the availability of certain DMTs [Disease-Modifying Therapies primarily used for multiple sclerosis and various autoimmune conditions (like rheumatoid arthritis)]. | 神经系统
> 多发性硬化症 | 改善访问路径
> 促进公平获取药品/医疗保健 | 10,000 | National | Regularly | 119074666617 |
| Equity of access: Public patients can wait a lot longer for access to meds approved by EMA [European Medicines Agency], versus private patients whose insurance companies reimburse. | 患者权益倡导
> 健康活动人士 | 改善访问路径
> 解决访问和管理方面的差距 | 1,000 | National | Sometimes | 119044976833 |
| Drugs for ataxia are very rare, so we only make submissions as they become available. | 神经退行性
> 共济失调 | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 1,000 | National | Rarely | 119020208311 |
| During the course of projects based on issues experienced by the community. | 胃肠道
> IBD | 循证患者意见
> 利用患者故事和亲身经历叙述 | 5,000 | National | Sometimes | 119020296590 |
| We share the patient experience of living with a condition as part of the reimbursement process. | 神经肌肉
> 神经肌肉疾病：大多数类型 | 循证患者意见
> 利用患者故事和亲身经历叙述 | 1,000 | National | Sometimes | 119047368493 |
互动
行动与倡导
9 提及
